Skip to content

CF-OGTT study

Performance and patient acceptance of a commercially available beverage as compared to an oral glucose solution for oral glucose tolerance tests in cystic fibrosis (CF) patients who are screened for CF-related diabetes. - CF-OGTT study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON51410
Enrollment
20
Registered
2021-11-16
Start date
2022-02-14
Completion date
Unknown
Last updated
2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CFRD, Cystic fibrosis, OGTT

Interventions

None listed

Sponsors

Amsterdam UMC
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >= 18 - Diagnosed with CF - One of the following: Diagnosed with CFRD or IGT based on a raise fasting glucose level or OGTT. Or; pancreatic insufficiency, without CFRD

Exclusion criteria

Exclusion criteria: - Age

Design outcomes

Primary

MeasureTime frame
Serum glucose levels at 120 minutes after ingestion of either the standard glucose solution or the sportsdrink.

Secondary

MeasureTime frame
- Serum glucose levels at 30, 60 and 90 minutes after ingestion of either the standard glucose solution or AA drink. - Patient satisfaction for the ingested test product using a VAS on the following points: overall satisfaction (very dissatisfied - very satisfied), taste (really bad - really good), ease of drinking (very difficult - very easy) and side effects after drinking (e.g. nauseousness, stomach ache) (very little - a lot).. - The percentage of patients with either CFRD or IGT according to results of either AATT of OGTT. - The optimal cut-off levels for the AATT using OGTT as a reference standard

Countries

Netherlands

Contacts

Public ContactJ. Altenburg

Amsterdam UMC

long@amsterdamumc.nl020-4444782

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)